6 June 2016 - Byvalson is the first and only fixed-dose combination of a beta blocker and angiotensin II receptor blocker for the treatment of hypertension.

Allergan today announced the approval of Byvalson (nebivolol and valsartan) 5 mg/ 80 mg tablets, by the U.S. FDA for the treatment of hypertension to lower blood pressure. Byvalson is the first and only fixed-dose combination of a beta blocker and angiotensin II receptor blocker available in the U.S.

For more details, go to: http://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-approval-of-byvalson-nebiv